Develops and produces enzymes and other proteins for various applications. Utilizes its patented and proprietary C1 platform technology for biomanufacturing. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 15% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 14.5× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 15% of them.
Analysts' average target sits 512% above today's price.
An investor who bought at the very peak is down 91% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 21 buys and 7 sells. Management buying with its own money is usually read as a good sign.
A loss of $7.4M against $1.2M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.49. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, DYAI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: DYAI’s sales are going backwards, and it closed last year at a loss. The road back runs through both.
Analysts’ average target sits above today’s price, yet the valuation grade (15/100) says the stock isn’t cheap.